Integra LifeSciences Holdings Corporation

NasdaqGS:IART Stock Report

Market Cap: US$1.8b

Integra LifeSciences Holdings Valuation

Is IART undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IART when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IART ($23.58) is trading below our estimate of fair value ($56.77)

Significantly Below Fair Value: IART is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IART?

Key metric: As IART is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IART. This is calculated by dividing IART's market cap by their current revenue.
What is IART's PS Ratio?
PS Ratio1.2x
SalesUS$1.56b
Market CapUS$1.77b

Price to Sales Ratio vs Peers

How does IART's PS Ratio compare to its peers?

The above table shows the PS ratio for IART vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.3x
NVCR NovoCure
3.3x9.4%US$1.8b
TNDM Tandem Diabetes Care
2.4x10.3%US$2.0b
OMCL Omnicell
2x6.0%US$2.0b
NUVA NuVasive
1.7x6.7%US$2.1b
IART Integra LifeSciences Holdings
1.2x5.8%US$1.8b

Price-To-Sales vs Peers: IART is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (2.6x).

Price to Sales Ratio vs Industry

How does IART's PS Ratio compare vs other companies in the US Medical Equipment Industry?

50 CompaniesPrice / SalesEstimated GrowthMarket Cap
INGN Inogen
0.7x4.2%US$219.37m
ARAY Accuray
0.4x5.5%US$190.07m
NVRO Nevro
0.4x2.5%US$163.38m
KEQU Kewaunee Scientific
0.6xn/aUS$122.83m
IART 1.2xIndustry Avg. 3.3xNo. of Companies50PS02.85.68.411.214+
50 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IART is good value based on its Price-To-Sales Ratio (1.2x) compared to the US Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is IART's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IART PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio2x

Price-To-Sales vs Fair Ratio: IART is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IART forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$23.58
US$28.11
+19.2%
22.7%US$40.00US$21.00n/a9
Nov ’25US$19.28
US$26.67
+38.3%
29.2%US$40.00US$16.00n/a9
Oct ’25US$17.50
US$27.30
+56.0%
25.4%US$40.00US$16.00n/a10
Sep ’25US$20.34
US$27.70
+36.2%
22.9%US$40.00US$20.00n/a10
Aug ’25US$24.61
US$28.20
+14.6%
20.6%US$40.00US$22.00n/a10
Jul ’25US$28.97
US$34.20
+18.1%
32.3%US$51.00US$24.00n/a10
Jun ’25US$30.90
US$34.20
+10.7%
32.3%US$51.00US$24.00n/a10
May ’25US$29.18
US$44.80
+53.5%
14.3%US$57.00US$37.00n/a10
Apr ’25US$34.72
US$44.80
+29.0%
14.3%US$57.00US$37.00n/a10
Mar ’25US$35.99
US$44.80
+24.5%
14.3%US$57.00US$37.00n/a10
Feb ’25US$40.92
US$46.60
+13.9%
14.5%US$57.00US$37.00n/a10
Jan ’25US$43.55
US$46.10
+5.9%
15.3%US$57.00US$37.00n/a10
Dec ’24US$41.02
US$43.27
+5.5%
14.9%US$55.00US$36.00n/a11
Nov ’24US$36.85
US$42.60
+15.6%
15.0%US$55.00US$36.00US$19.2810
Oct ’24US$38.19
US$47.20
+23.6%
12.9%US$60.00US$39.00US$17.5010
Sep ’24US$42.76
US$47.20
+10.4%
12.9%US$60.00US$39.00US$20.3410
Aug ’24US$44.95
US$47.20
+5.0%
12.9%US$60.00US$39.00US$24.6110
Jul ’24US$41.13
US$47.90
+16.5%
16.2%US$65.00US$39.00US$28.9710
Jun ’24US$38.42
US$49.00
+27.5%
16.1%US$65.00US$39.00US$30.9010
May ’24US$55.63
US$57.80
+3.9%
8.3%US$66.00US$50.00US$29.1810
Apr ’24US$57.41
US$59.00
+2.8%
11.5%US$75.00US$50.00US$34.7210
Mar ’24US$54.82
US$59.00
+7.6%
11.5%US$75.00US$50.00US$35.9910
Feb ’24US$58.57
US$58.40
-0.3%
12.4%US$75.00US$50.00US$40.9210
Jan ’24US$56.07
US$56.90
+1.5%
13.8%US$75.00US$50.00US$43.5510
Dec ’23US$56.36
US$54.50
-3.3%
15.3%US$75.00US$48.00US$41.0210
Nov ’23US$50.95
US$54.50
+7.0%
15.3%US$75.00US$48.00US$36.8510

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Elevance Health

US$93.6b

Operates as a health benefits company in the United States.

ELV

US$402.55

7D

0.5%

1Y

-15.9%

Lantheus Holdings

US$6.1b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.52

7D

17.8%

1Y

31.5%

electroCore

US$64.0m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

7D

2.5%

1Y

101.6%